Opposing effects of growth hormone and insulin-like growth factor I on serum lipoprotein(a)

Journal of Pediatric Endocrinology and Metabolism

Volumn 10, Issue SUPPL. 1, 1997, Pages 143-149

  Laron, Zvi ^a   Klinger, Beatrice ^a   Silbergeld, Aviva ^b   Wang, Xing Li ^c  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

chronic renal failure; GH; GH deficiency; GH treatment; IGF I; IGF I treatment; Laron syndrome; lipoprotein(a); short stature

Indexed keywords

APOLIPOPROTEIN A; GROWTH HORMONE; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C;

ADOLESCENT; ADULT; CEREBROVASCULAR DISEASE; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN RELEASE; INSULIN RESPONSE; LARON SYNDROME; LIPOPROTEIN BLOOD LEVEL; MALE; NEGATIVE FEEDBACK; PERIPHERAL VASCULAR DISEASE; SHORT STATURE;

EID: 0030920530     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.1997.10.s1.143     Document Type: Conference Paper

References (46)

1. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease (Review). Atherosclerosis 1994; 108: 111-126.
2. Utermann G. The mysteries of lipoprotein(a) (Review). Science 1989; 246: 904-910.
3. Wang XL, Tam C, McCredie RM, Wilcken DEL. Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994; 89: 1974-1981.
4. Van Kooten F, Van Krimpen J, Dippel DW, Hoggerbrugge N, Koudstaal PJ. Lipoprotein(a) in patients with acute cerebral ischaemia. Stroke 1996; 27: 1231-1250.
5. Assmann G, Schulte H, Von Eckardstein A. Hyper-triglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-1184.
6. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-592.
7. Harpel PC, Hermann A, Zhang X, Ostfeld I, Borth W. Lipoprotein(a), plasmin modulation and atherogenesis. Thromb Haemotol 1995; 74: 382-386.
8. Valentine RJ, Kaplan HS, Green R, Jacobson DW, Myers SI, Clagett GP. Lipoprotein, homocysteine and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. J Vascul Surg 1996; 23: 53-61.
9. Sorensen KE, Celermajer DS, Georkakopoulos D, Hatcher G, Betteridge DI, Deanfield JE. Impairment of endothelium dependent dilation is an early event in children with familiar hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994; 93: 50-55.
10. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-462.
11. Nielsen LB, Slender S, Kjelsden K, Nordgestgaard BG. Specific accumulation of lipopiotein(a) in balloon-injured rabbit aorta in vivo. Circ Res 1996; 78: 615-616.
12. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60.
13. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Aba A, Muhlberger V, Schonitzer D, Utermenn G.. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 713-719
14. Wade DP, Clarke JG, Lindhal GE, Liu AL, Zyson BR, Meer K, Schwartz K, Lawn RM. 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen family. Proc Natl Acad Sci USA 1993; 90: 1369-1373.
15. Routi T, Ronnemaa T, Salo P, Seppanen R, Marniemi J, Viikari J, Ehnholm C, Simell O. Effects of prospective, randomized cholesterol-lowering dietary intervention and apolopoprotein E phenotype on serum lipoprotein(a) concentrations of infants aged 7-24 mo. Am J Clin Nutr 1996; 63: 386-391.
16. Berglund L, Carlstrom K, Stege R, Gottlieb C, Eriksson M, Angelin B, Henriksson P. Hormonal regulation of serum lipoprotein(a) levels: effect of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996; 81: 2633-2637.
17. Dullart RP, Van Doormaal JJ, Hoogenberg K, Sluiter WJ. Triiodothyronine rapidly lowers plasma lipoprotein(a) in hypothyroid subjects. Netherlands J Med 1995; 46: 179-184.
18. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Ukena T, Weale V, Baker S. Taximofen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994; 14: 1586-1593.
19. Kuusi T, Yki-Jarvinen H, Kauppinen-Makelin R, Jauhiainen M, Ehnholm C, Kauppila M, Seppala P, Viikari J, Kujansuu E, Rajala S, Lahti J, Niskanen L, Marjanen I, Salo S, Ryysy L, Tuloka T, Taskinen MR. Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. Eur J Clin Invest 1995; 25: 194-200.
20. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Growth hormone increases and insulin like growth factor decreases circulating lipoprotein(a). Eur J Endocrinol (in press).
21. Laron Z, Klinger B, Silbergeld A, Wilcken DEL, Wang XL. IGF-I and hGH have opposing effects on serum lipoprotein(a). J Pediatr Endocrinol Metab 1996; 9: 218. Abstract #47.
22. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. IGF-I lowers and hGH raises serum lipoprotein(a). Diabetes 1996; 45 (Suppl 2): 317A. Abstract #1182.
23. Oscarsson J, Ottoson M, Wiklund O, Marin P, Vikman-Adolfssen K, Bjoerntorp P, Edén S. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men. Clin Endocrinol 1994; 41: 109-116.
24. Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B. Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth fector I. Arterioscler Thromb Vasc Biol 1995; 15: 847-849.
25. Johannsson G, Oscarsson J, Rosen T, Wiklund O, Olsson G, Wilhelmsen L, Bengtsson BA. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in grown hormone-deficient adults. Influence of gender and apo(a) and apoE phenotypes. Arterioscler Thromb Vasc Biol 1995; 15: 2142-2150.
26. Garry P, Collins P, Devlin JG. An open 36 month study of lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 1996; 134: 61-66.
27. Hershovitz E, Leiberman E, Limony Y, Shany SH, Phillip M. Short-term growth hormone increases serum lipoprotein(a) levels in normal short children without growth hormone deficiency. Horm Res 1996; 46: 38-40.
28. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Insulin-like growth factor I lowers serum lipoprotein(a) during long-term treatment of patients with Laron syndrome. Metabolism 1996; 45: 1-5.
29. Oscarsson J, Lundstam U, Gustavsson B, Wilton P, Edén S, Wiklund O. Recombinant human insulin-like growth fector-I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol 1995; 42: 673-676.
30. Wang XL, Wilcken DEL, Dudman NAB. An indirect sandwich ELISA for serum and dried blot spot Lp(a) measurements, comparison to a commercial RIA. Clin Chem Acta 1992; 207: 73-86.
31. Laron Z, Klinger B, Silbergeld A, Lewin B, Erster B, Gil-Ad I. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990; 123: 378-382.
32. Caprio S, Boulware D, Tamborlane W. Growth hormone and insulin interactions. Horm Res 1992; 38 (Suppl 2): 447-449.
33. Laron Z, Klinger B, Jensen LT, Erster B. Biochemical and hormonal changes induced by one week of administration of IGF-I to patients with Laron type dwarfism. Clin Endocrinol 1991; 35: 145-150.
34. Klinget B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-158.
35. Sutherland WH, Lewis-Barned NJ, Pratt MC, Tillman HC, Walker RJ. The response of plasma lipoprotein(a) concentration to acute hyperinsulinemia in patients with non-insulin dependent diabetes and in healthy subjects. Comm Chem Path Pharmacol 1994; 83: 77-86.
36. Gafny M, Silbergeld A, Klinger B, Wasserman M, Laron Z. Comparative effects of GH, IGF-I and insulin on hormone binding globulin. Clin Endocrinol 1994; 41: 169-175.
37. Laron Z, Wang XL, Klinger B, Silbergeld A, Davidovits M, Eisenstein B, Wilcken DEL. Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure. J Pediatr Endocrinol Metab 1996; 9: 533-538.
38. Frohman LA. Diseases of the anterior pituitary. In: Felig P, Baxter JD, Broadus AE, Frohman LA, eds. Endocrinology and Metabolism, 2nd Ed. New-York: McGraw-Hill Book Co., 1987; 247-337.
39. Adeli K, Theriault A. Insulin modulation of human apolipoprotein B mRNA translation: studies in an in vitro cell-free system from HepG2 cells. Biochem Cell Biol 1992; 70: 1301-1312.
40. White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary baboon hepatocytes. J Biol Chem 1994; 269: 28716-28723.
41. Laron Z, Butenandt O. Optimum use of growth hormone in children (Review). Drugs 1991; 42: 1-8.
42. Bengtsson BA, Edén S, Lonn L, Kvist H, Stockland A, Lindstedt G, Bosacus I, Tolli J, Sjostrom L, Isaksson OGP. Treatment of adults with growth hormone (GH) deficiency with recombinant GH. J Clin Endocrinol Metab 1993; 76: 309-317.
43. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R. Effects of recombinant human growth hormone on metabolic indices, body conposition and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994; 79: 470-479.
44. Laron Z. Growth hormone secretagogues. Clinical experience and therapeutic potential. Drugs 1995; 50: 595-601.
45. Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? Clin Endocrinol 1995; 43: 143-149.
46. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. JAMA 1996; 276: 544-548.